PyRxia™ has filed 8 provisional patents covering the integrated system, its core subsystems, an AI-driven dosimetry engine, and wearable post-treatment monitoring — with non-provisional filings planned. The addressable market for metastatic cancer therapeutics spans tens of billions of dollars globally.
Sources: Mordor Intelligence, Metastatic Cancer Treatment Market ($91.44B in 2026, growing to $134.39B by 2031); Allied Market Research, Metastatic Cancer Drugs Market ($67.7B in 2022, growing to $136.9B by 2032); Fortune Business Insights, Oncology Drugs Market Size, Share & Growth Forecast ($286.36B in 2026, broader oncology drug market context).
PyRxia™ is raising a Series A financing round to complete development of our platform and build out our commercial launch. If you are an accredited investor interested in learning more, we'd love to hear from you.
Request Investor InformationBuilt on a proven therapeutic modality with decades of supporting research.
Layered, defensible patent portfolio across hardware, software, and method claims.
Leadership with a track record across medical device commercialization and regulatory approval.
Strategic fit for oncology pharma, medtech, and immuno-oncology acquirers.